Glycorex Transplantation AB (publ) is a medical technology company involved in development, production and sales in the fields of organ transplantation and other closely related disciplines.

The company’s main product – Glycosorb^®-ABO – has been in use since 2001. Since then, more than 130 transplant centres in 23 countries have adopted the product and performed approximately 2,000 transplants with excellent results with the help of the product. Using Glycosorb^®-ABO, organs can be transplanted from a donor with a different blood group from that of the recipient, something that was practically impossible in the past. In practice, this means that the number of transplants that can be done is increasing significantly. 

For the patients, a transplant often means a higher quality of life and a longer expected survival time. At the same time, the treatment is cost-effective and this leads to considerable cost-savings for the health-care system and for society compared with giving alternative treatments.